Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217990 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT07217990: Clinical Trial Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT07217990 is a Phase 1 study that has not yet begun recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217990, a Phase 1 study, has not yet begun recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.
Primary Outcome
The study endpoints of disease-free rate and locoregional control will be determined in patient follow up by utilizing MRIs, annual mammograms and clinical assessments in conjunction with ctDNA status.
Interventions
- PROCEDURE Biopsy
- RADIATION Radiation Therapy
- PROCEDURE MRI
- DRUG Neoadjuvant Chemotherapy
- PROCEDURE Breast Cancer Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What is known before NCT07217990 opens enrollment
NCT07217990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 5 interventions - of which Biopsy is the first listed.
NCT07217990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07217990 about?
NCT07217990 is a clinical study titled "Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer". This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.
What is the current status of trial NCT07217990?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-09-15. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07217990?
The interventions under investigation include: Biopsy (PROCEDURE), Radiation Therapy (RADIATION), MRI (PROCEDURE), Neoadjuvant Chemotherapy (DRUG), Breast Cancer Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT07217990?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07217990's enrollment target sits among peer trials
84 659th of 2000 higher than 1,336 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI